Comparative Analysis of Pharmaceutical Pricing Regulation Across Health Systems

Authors

  • Roth J Department of Health Economics, University of Hamburg, Hamburg, Germany Author
  • Visser B Department of Health Policy, Radboud University, Nijmegen, Netherlands Author
  • Karagiannis M Department of Pharmacoeconomics, National and Kapodistrian University of Athens, Athens, Greece Author

DOI:

https://doi.org/10.5281/zenodo.22655719

Keywords:

pharmaceutical pricing, reference pricing, managed-entry agreements;, drug price negotiation, health technology assessment

Abstract

Background: Rising pharmaceutical expenditure has driven health systems to adopt a heterogeneous set of pricing and
reimbursement regulation instruments, including external and internal reference pricing, value-based and managed-entry
agreements, and, increasingly, direct government price negotiation, most notably Germany's AMNOG framework and the United
States' Medicare Drug Price Negotiation Program established by the 2022 Inflation Reduction Act (IRA). Objective: To synthesize
peer-reviewed comparative evidence on the design and consequences of pharmaceutical pricing regulation across health systems,
focusing on effects on price levels, patient access, and innovation incentives. Methods: A narrative review of peer-reviewed
literature on external and internal reference pricing, value-based and managed-entry agreements, direct negotiation models, and
cross-country comparative price and launch-timing studies, drawing on health economics, health policy, and clinical policy
journals. Twenty-two individually verified studies met inclusion criteria. Findings: External reference pricing is nearly universally
adopted across European and many middle-income health systems, but recent empirical evidence questions its reliability in
reducing domestic prices and documents substantial unintended cross-border spillover effects. Internal reference pricing exerts
more consistent downward pressure on within-cluster prices but can induce upward convergence of generic prices toward the
reference level. Managed-entry agreements, predominantly financial rather than outcomes-based in practice, help manage
launch-price uncertainty but further obscure net prices through confidential rebates. Direct negotiation under Germany's
decade-tested AMNOG framework moderates but does not eliminate a price premium for drugs of unproven additional benefit
relative to comparator therapy, a finding with direct relevance to the design and likely trajectory of the newly implemented US
Medicare negotiation program. Cross-country studies consistently link more stringent, externally referenced price regulation to
delayed and less complete global product launch, with plausible but not yet directly measured implications for pharmaceutical
research and development incentives. Conclusions: No single pricing instrument reviewed optimizes simultaneously across cost
containment, access, and innovation objectives; each generates measurable gains on some dimensions alongside documented
trade-offs on others. Policymakers should treat these instruments as complementary components of a layered regulatory
architecture and prioritize transparent, internationally comparable net-price data as a precondition for rigorous future
evaluation.

References

Rome BN, Nagar S, Egilman AC, Wang J, Feldman WB, Kesselheim AS (2023) Simulated Medicare drug price negotiation under the Inflation Reduction Act of 2022. JAMA Health Forum, 4(1):e225218, DOI:10.1001/jamahealthforum.2022.5218.

Dusetzina SB, Huskamp HA (2022) Impending relief for Medicare beneficiaries — the Inflation Reduction Act. New England Journal of Medicine, 387(16):1437-1439, DOI:10.1056/NEJMp2211223.

Vogler S (2013) Discounts and rebates granted for medicines for hospital use in five European countries. Open Pharmacoeconomics & Health Economics Journal, 5(1):1-10, DOI:10.2174/1876824501305010001.

Kanavos P, Ferrario A, Vandoros S, Anderson GF (2013) Higher US branded drug prices and spending compared to other countries may stem partly from quick uptake of new drugs. Health Affairs, 32(4):753-761, DOI:10.1377/hlthaff.2012.0920.

Rémuzat C, Urbinati D, Mzoughi O, El Hammi E, Belgaied W, Toumi M (2015) Overview of external reference pricing systems in Europe. Journal of Market Access & Health Policy, 3(1):27675, DOI:10.3402/jmahp.v3.27675.

Kanavos P, Fontrier AM, Gill J, Efthymiadou O (2019) Does external reference pricing deliver what it promises? Evidence on its impact at national level. European Journal of Health Economics, 21(1):129-151, DOI:10.1007/s10198-019-01116-4.

Fontrier AM, Gill J, Kanavos P (2019) International impact of external reference pricing: should national policy-makers care? European Journal of Health Economics, 20(8):1147-1164, DOI:10.1007/s10198-019-01083-w.

Puig-Junoy J (2010) Impact of European pharmaceutical price regulation on generic price competition: a review. PharmacoEconomics, 28(8):649-663, DOI:10.2165/11535360-000000000-00000.

Kanavos P, Reinhardt U (2003) Reference pricing for drugs: is it compatible with U.S. health care? Health Affairs, 22(3):16-30, DOI:10.1377/hlthaff.22.3.16.

Claxton K, Martin S, Soares M, Rice N, Spackman E, Hinde S, Devlin N, Smith PC, Sculpher M (2015) Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold. Health Technology Assessment, 19(14):1-503, DOI:10.3310/hta19140.

Neumann PJ, Cohen JT, Weinstein MC (2014) Updating cost-effectiveness — the curious resilience of the $50,000-per-QALY threshold. New England Journal of Medicine, 371(9):796-797, DOI:10.1056/NEJMp1405158.

Garrison LP, Towse A, Briggs A, de Pouvourville G, Grueger J, Mohr PE, Severens JL, Siviero P, Sleeper M (2013) Performance-based risk-sharing arrangements—good practices for design, implementation, and evaluation: report of the ISPOR Good Practices for Performance-Based Risk-Sharing Arrangements Task Force. Value in Health, 16(5):703-719, DOI:10.1016/j.jval.2013.04.011.

Ferrario A, Kanavos P (2015) Dealing with uncertainty and high prices of new medicines: a comparative analysis of the use of managed entry agreements in Belgium, England, the Netherlands and Sweden. Social Science & Medicine, 124:39-47, DOI:10.1016/j.socscimed.2014.11.003.

Lauenroth VD, Stargardt T (2017) Pharmaceutical pricing in Germany: how is value determined within the scope of AMNOG? Value in Health, 20(7):927-935, DOI:10.1016/j.jval.2017.04.006.

Kleining K, Laufenberg J, Thrun P, Ehlert D, Wasem J, Bartol A (2024) Ten years of German benefit assessment: price analysis for drugs with unproven additional benefit. Health Economics, Policy and Law, 19(2):216-233, DOI:10.1017/S1744133123000117.

Danzon PM, Furukawa MF (2008) International prices and availability of pharmaceuticals in 2005. Health Affairs, 27(1):221-233, DOI:10.1377/hlthaff.27.1.221.

Cameron A, Ewen M, Ross-Degnan D, Ball D, Laing R (2009) Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis. Lancet, 373(9659):240-249, DOI:10.1016/S0140-6736(08)61762-6.

Kanavos P, Vandoros S (2011) Determinants of branded prescription medicine prices in OECD countries. Health Economics, Policy and Law, 6(3):337-367, DOI:10.1017/S1744133111000090.

Danzon PM, Wang YR, Wang L (2005) The impact of price regulation on the launch delay of new drugs—evidence from twenty-five major markets in the 1990s. Health Economics, 14(3):269-292, DOI:10.1002/hec.931.

Kyle MK (2007) Pharmaceutical price controls and entry strategies. Review of Economics and Statistics, 89(1):88-99, DOI:10.1162/rest.89.1.88.

Danzon PM, Towse A (2003) Differential pricing for pharmaceuticals: reconciling access, R&D and patents. International Journal of Health Care Finance and Economics, 3(3):183-205, DOI:10.1023/A:1025384819575.

Vogler S, Vitry A, Babar ZUD (2016) Cancer drugs in 16 European countries, Australia, and New Zealand: a cross-country price comparison study. Lancet Oncology, 17(1):39-47, DOI:10.1016/S1470-2045(15)00449-0.

Downloads

Published

2024-12-31